Compare ADAM & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADAM | GERN |
|---|---|---|
| Founded | 2003 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 634.9M | 753.3M |
| IPO Year | N/A | 1996 |
| Metric | ADAM | GERN |
|---|---|---|
| Price | $7.29 | $1.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $7.50 | $3.00 |
| AVG Volume (30 Days) | 751.3K | ★ 7.0M |
| Earning Date | 02-18-2026 | 11-05-2025 |
| Dividend Yield | ★ 12.62% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $216,781,000.00 | $183,403,000.00 |
| Revenue This Year | $13.60 | $147.42 |
| Revenue Next Year | $49.42 | $39.42 |
| P/E Ratio | $37.63 | ★ N/A |
| Revenue Growth | N/A | ★ 522.13 |
| 52 Week Low | $5.02 | $1.04 |
| 52 Week High | $7.75 | $3.68 |
| Indicator | ADAM | GERN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 58.64 |
| Support Level | N/A | $1.30 |
| Resistance Level | N/A | $1.37 |
| Average True Range (ATR) | 0.00 | 0.08 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 68.75 |
Adamas Trust Inc is an internally-managed REIT for U.S. federal income tax purposes, in the business of acquiring, investing in, financing and managing primarily mortgage-related single-family and multi-family residential assets. Its objective is to deliver long-term stable distributions to its stockholders over changing economic conditions through a combination of net interest spread and capital gains from a diversified investment portfolio. The company's investment portfolio includes credit sensitive single-family and multi-family assets.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.